Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy – Myeloma Research News
Myeloma Research News |
Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy
Myeloma Research News The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership between bluebird bio and Celgene. The companies will share the … |
